Frankly if the pipeline works half as well as appears early on...
...ISIS should be valued at $30B ($300 per share).
It's the goose that lays the golden eggs.
News from today's call. STAT3rx has two (2 of 2) durable partial responses in diffuse large b-cell lymphoma. This means at least a 50% shrinkage of tumor lasting six months are more. This is exceptional early data. It's approaching unprecedented. Prepare for major buzz near term, possibly by ASCO.